Copenhagen, 2011-12-15 08:22 CET (GLOBE NEWSWIRE) --

Pursuant to section 29 of the Danish Securities Trading Act, ALK has received
notification from Lundbeckfond Invest A/S that Lundbeckfond Invest A/S,
Hellerup, Denmark, has increased its ownership in ALK-Abelló A/S.

Lundbeckfond Invest A/S now owns 39.40% of the company share capital equivalent
to 920,720 A shares and 3,069,680 B shares, and 66.67% of the votes.

ALK-Abelló A/S



Jens Bager
President and CEO


For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy – a unique treatment of the underlying cause of allergy. The
company has approximately 1,750 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii Pharmaceutical Co. Ltd. to commercialise
allergy immunotherapy tablets in North America and Japan, respectively. The
company is headquartered in Hørsholm, Denmark, and listed on the NASDAQ OMX
Copenhagen A/S. Find more information at www.alk-abello.com.

FM_26_11UK_15122011.pdf